Thrombotic microangiopathy after GVHD prophylaxis with tacrolimus/sirolimus: a call for use of consensus definition in reporting.
Kharfan-Dabaja
Mohamed A
MA
Pidala
Joseph
J
Anasetti
Claudio
C
D006801:Humans; D006086:Graft vs Host Disease / Q000517:prevention & control; D018380:Hematopoietic Stem Cell Transplantation; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000097:blood; D012307:Risk Factors; D020123:Sirolimus / Q000009:adverse effects / Q000097:blood; D016559:Tacrolimus / Q000009:adverse effects / Q000097:blood; D057049:Thrombotic Microangiopathies / Q000139:chemically induced / Q000175:diagnosis; D019172:Transplantation Conditioning / Q000379:methods
D007166:Immunosuppressive Agents; D020123:Sirolimus; D016559:Tacrolimus